Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state.

Furth N, Pateras IS, Rotkopf R, Vlachou V, Rivkin I, Schmitt I, Bakaev D, Gershoni A, Ainbinder E, Leshkowitz D, Johnson RL, Gorgoulis VG, Oren M, Aylon Y.

Life Sci Alliance. 2018 Oct 30;1(5):e201800171. doi: 10.26508/lsa.201800171. eCollection 2018 Oct.

2.

Corrigendum: p53 is essential for DNA methylation homeostasis in naïve embryonic stem cells, and its loss promotes clonal heterogeneity.

Tovy A, Spiro A, McCarthy R, Shipony Z, Aylon Y, Allton K, Ainbinder E, Furth N, Tanay A, Barton M, Oren M.

Genes Dev. 2018 Oct 1;32(19-20):1358. doi: 10.1101/gad.319863.118. No abstract available.

3.

TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.

Jethwa A, Słabicki M, Hüllein J, Jentzsch M, Dalal V, Rabe S, Wagner L, Walther T, Klapper W; MMML Network Project, Bohnenberger H, Rettel M, Lu J, Smits AH, Stein F, Savitski MM, Huber W, Aylon Y, Oren M, Zenz T.

Blood. 2018 Jun 21;131(25):2789-2802. doi: 10.1182/blood-2017-09-806679. Epub 2018 Apr 13.

PMID:
29653964
4.

Corrigendum: The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.

Shema E, Tirosh I, Aylon Y, Huang J, Ye C, Moskovits N, Raver-Shapira N, Minsky N, Pirngruber J, Tarcic G, Hublarova P, Moyal L, Gana-Weisz M, Shiloh Y, Yarden Y, Johnsen SA, Vojtesek B, Berger SL, Oren M.

Genes Dev. 2017 Sep 15;31(18):1926. doi: 10.1101/gad.307207.117. No abstract available.

5.

Tumor Suppression by p53: Bring in the Hippo!

Aylon Y, Oren M.

Cancer Cell. 2017 Oct 9;32(4):397-399. doi: 10.1016/j.ccell.2017.09.010.

6.

p53 shades of Hippo.

Furth N, Aylon Y, Oren M.

Cell Death Differ. 2018 Jan;25(1):81-92. doi: 10.1038/cdd.2017.163. Epub 2017 Oct 6. Review.

PMID:
28984872
7.

The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway.

Furth N, Aylon Y.

Cell Death Differ. 2017 Sep;24(9):1488-1501. doi: 10.1038/cdd.2017.99. Epub 2017 Jun 23. Review.

8.

p53 is essential for DNA methylation homeostasis in naïve embryonic stem cells, and its loss promotes clonal heterogeneity.

Tovy A, Spiro A, McCarthy R, Shipony Z, Aylon Y, Allton K, Ainbinder E, Furth N, Tanay A, Barton M, Oren M.

Genes Dev. 2017 May 15;31(10):959-972. doi: 10.1101/gad.299198.117. Epub 2017 Jun 12. Erratum in: Genes Dev. 2018 Oct 1;32(19-20):1358.

9.

The Hippo pathway, p53 and cholesterol.

Aylon Y, Oren M.

Cell Cycle. 2016 Sep;15(17):2248-55. doi: 10.1080/15384101.2016.1207840. Epub 2016 Jul 15. Review.

10.

The Paradox of p53: What, How, and Why?

Aylon Y, Oren M.

Cold Spring Harb Perspect Med. 2016 Oct 3;6(10). pii: a026328. doi: 10.1101/cshperspect.a026328. Review.

11.

The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation.

Aylon Y, Gershoni A, Rotkopf R, Biton IE, Porat Z, Koh AP, Sun X, Lee Y, Fiel MI, Hoshida Y, Friedman SL, Johnson RL, Oren M.

Genes Dev. 2016 Apr 1;30(7):786-97. doi: 10.1101/gad.274167.115. Epub 2016 Mar 24.

12.

Down-regulation of LATS kinases alters p53 to promote cell migration.

Furth N, Bossel Ben-Moshe N, Pozniak Y, Porat Z, Geiger T, Domany E, Aylon Y, Oren M.

Genes Dev. 2015 Nov 15;29(22):2325-30. doi: 10.1101/gad.268185.115.

13.

Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth.

Adi Harel S, Bossel Ben-Moshe N, Aylon Y, Bublik DR, Moskovits N, Toperoff G, Azaiza D, Biagoni F, Fuchs G, Wilder S, Hellman A, Blandino G, Domany E, Oren M.

Cell Death Differ. 2015 Aug;22(8):1328-40. doi: 10.1038/cdd.2014.221. Epub 2015 Jan 16.

14.

Lats2 is critical for the pluripotency and proper differentiation of stem cells.

Aylon Y, Sarver A, Tovy A, Ainbinder E, Oren M.

Cell Death Differ. 2014 Apr;21(4):624-33. doi: 10.1038/cdd.2013.188. Epub 2014 Jan 10.

15.

Lats2 phosphorylates p21/CDKN1A after UV irradiation and regulates apoptosis.

Suzuki H, Yabuta N, Okada N, Torigata K, Aylon Y, Oren M, Nojima H.

J Cell Sci. 2013 Oct 1;126(Pt 19):4358-68. doi: 10.1242/jcs.125815. Epub 2013 Jul 25.

16.

p53: guardian of ploidy.

Aylon Y, Oren M.

Mol Oncol. 2011 Aug;5(4):315-23. doi: 10.1016/j.molonc.2011.07.007. Epub 2011 Jul 30. Review.

17.

The tumor suppressor Lats2 is pivotal in Aurora A and Aurora B signaling during mitosis.

Yabuta N, Mukai S, Okada N, Aylon Y, Nojima H.

Cell Cycle. 2011 Aug 15;10(16):2724-36. Epub 2011 Aug 15.

PMID:
21822051
18.

New plays in the p53 theater.

Aylon Y, Oren M.

Curr Opin Genet Dev. 2011 Feb;21(1):86-92. doi: 10.1016/j.gde.2010.10.002. Epub 2010 Nov 4. Review.

19.

A novel Chk1/2-Lats2-14-3-3 signaling pathway regulates P-body formation in response to UV damage.

Okada N, Yabuta N, Suzuki H, Aylon Y, Oren M, Nojima H.

J Cell Sci. 2011 Jan 1;124(Pt 1):57-67. doi: 10.1242/jcs.072918. Epub 2010 Nov 30.

20.

The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1.

Aylon Y, Ofir-Rosenfeld Y, Yabuta N, Lapi E, Nojima H, Lu X, Oren M.

Genes Dev. 2010 Nov 1;24(21):2420-9. doi: 10.1101/gad.1954410.

21.

Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation.

Aylon Y, Yabuta N, Besserglick H, Buganim Y, Rotter V, Nojima H, Oren M.

Oncogene. 2009 Dec 17;28(50):4469-79. doi: 10.1038/onc.2009.270. Epub 2009 Oct 26.

22.

CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3'-end processing.

Pirngruber J, Shchebet A, Schreiber L, Shema E, Minsky N, Chapman RD, Eick D, Aylon Y, Oren M, Johnsen SA.

EMBO Rep. 2009 Aug;10(8):894-900. doi: 10.1038/embor.2009.108. Epub 2009 Jul 3.

23.

The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.

Shema E, Tirosh I, Aylon Y, Huang J, Ye C, Moskovits N, Raver-Shapira N, Minsky N, Pirngruber J, Tarcic G, Hublarova P, Moyal L, Gana-Weisz M, Shiloh Y, Yarden Y, Johnsen SA, Vojtesek B, Berger SL, Oren M.

Genes Dev. 2008 Oct 1;22(19):2664-76. doi: 10.1101/gad.1703008. Erratum in: Genes Dev. 2017 Sep 15;31(18):1926.

24.

Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy.

Finkin S, Aylon Y, Anzi S, Oren M, Shaulian E.

Oncogene. 2008 Jul 24;27(32):4411-21. doi: 10.1038/onc.2008.77. Epub 2008 Apr 7.

PMID:
18391985
25.

Living with p53, dying of p53.

Aylon Y, Oren M.

Cell. 2007 Aug 24;130(4):597-600. Review.

27.

A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization.

Aylon Y, Michael D, Shmueli A, Yabuta N, Nojima H, Oren M.

Genes Dev. 2006 Oct 1;20(19):2687-700.

28.

Cell cycle-dependent regulation of double-strand break repair: a role for the CDK.

Aylon Y, Kupiec M.

Cell Cycle. 2005 Feb;4(2):259-61. Epub 2005 Feb 7.

PMID:
15655342
29.

The CDK regulates repair of double-strand breaks by homologous recombination during the cell cycle.

Aylon Y, Liefshitz B, Kupiec M.

EMBO J. 2004 Dec 8;23(24):4868-75. Epub 2004 Nov 18.

30.

DSB repair: the yeast paradigm.

Aylon Y, Kupiec M.

DNA Repair (Amst). 2004 Aug-Sep;3(8-9):797-815. Review.

PMID:
15279765
31.

New insights into the mechanism of homologous recombination in yeast.

Aylon Y, Kupiec M.

Mutat Res. 2004 May;566(3):231-48. Review.

PMID:
15082239
33.

Molecular dissection of mitotic recombination in the yeast Saccharomyces cerevisiae.

Aylon Y, Liefshitz B, Bitan-Banin G, Kupiec M.

Mol Cell Biol. 2003 Feb;23(4):1403-17.

34.

Analysis of the promoter of the MUC1 gene overexpressed in breast cancer.

Zaretsky JZ, Sarid R, Aylon Y, Mittelman LA, Wreschner DH, Keydar I.

FEBS Lett. 1999 Nov 19;461(3):189-95.

Supplemental Content

Support Center